TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Acumen Pharmaceuticals, Inc. (ABOS) stock has reached a new 52-week low, trading at $1.28, with a market capitalization of $77.2 million. This latest price level reflects a significant downturn for the company, which has seen its stock value decrease by 63.2% over the past year. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value assessment. Investors are closely monitoring ABOS as it navigates through a challenging period in the market. While the company maintains a strong current ratio of 10.43 and holds more cash than debt, it’s quickly burning through its cash reserves. The 52-week low serves as a critical point of analysis, with analysts setting price targets between $6 and $15. InvestingPro subscribers can access 12 additional key insights about ABOS’s financial health and future prospects through the comprehensive Pro Research Report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.